Company Performance - Moderna's stock closed at $33.64, down 1.87%, underperforming the S&P 500's daily loss of 0.33% [1] - Over the previous month, Moderna's shares gained 25.34%, outperforming the Medical sector's loss of 0.32% and the S&P 500's gain of 4.07% [1] Upcoming Earnings - The upcoming earnings release is anticipated, with an expected EPS of -$2.97, reflecting a 10.81% increase from the same quarter last year [2] - Revenue is forecasted at $130.15 million, indicating a 46% decline compared to the same quarter last year [2] Full-Year Estimates - Zacks Consensus Estimates predict full-year earnings of -$9.81 per share and revenue of $2.08 billion, representing year-over-year changes of -10.6% and -35.83%, respectively [3] - Recent changes in analyst estimates are crucial for investors, as positive revisions indicate optimism regarding business and profitability [3] Zacks Rank System - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has shown a strong track record, with 1 stocks delivering an average annual return of +25% since 1988 [5] - Currently, Moderna holds a Zacks Rank of 3 (Hold), with the consensus EPS estimate moving 0.26% lower over the last 30 days [5] Industry Overview - The Medical - Biomedical and Genetics industry ranks in the top 31% of all industries, with a current Zacks Industry Rank of 76 [6] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Certara, Inc. (CERT) , which belongs to the Zacks Medical - Biomedical and Genetics industry.When looking at the last two reports, this company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 11.54%, on average, in the last two quarters.For the last reported quarter, Certara came out with earnings of $0.14 pe ...

Ginkgo Bioworks Holdings, Inc. (DNA) ended the recent trading session at $10.79, demonstrating a -2.53% change from the preceding day's closing price. This move lagged the S&P 500's daily gain of 0.28%. On the other hand, the Dow registered a gain of 0.43%, and the technology-centric Nasdaq increased by 0.09%. The stock of company has risen by 13.19% in the past month, leading the Medical sector's gain of 0.24% and the S&P 500's gain of 4.37%.The investment community will be closely monitoring the performan ...

Company Overview - Anavex Life Sciences (AVXL) currently holds a Momentum Style Score of A, indicating strong momentum characteristics [3] - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook compared to the market [4] Performance Metrics - Over the past week, AVXL shares have increased by 13.82%, significantly outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by 2.88% [6] - In a longer time frame, AVXL's shares have shown a monthly price change of 31.22%, while the industry only experienced a 0.29% increase [6] - For the past quarter, AVXL shares have risen by 21.72%, and over the last year, they have gained 132.9%, compared to the S&P 500's increases of 15.13% and 13.62%, respectively [7] Trading Volume - The average 20-day trading volume for AVXL is 910,751 shares, which serves as a useful indicator of market interest and price movement [8] Earnings Outlook - In the past two months, one earnings estimate for AVXL has been revised upward, while none have been revised downward, leading to an increase in the consensus estimate from -$0.69 to -$0.52 [10] - For the next fiscal year, one estimate has moved upwards with no downward revisions during the same period [10] Conclusion - Considering the strong performance metrics and positive earnings outlook, AVXL is positioned as a promising investment opportunity with a Momentum Score of A [12]

Beam Therapeutics Inc. (BEAM) shares ended the last trading session 5.7% higher at $21.46. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 12.3% gain over the past four weeks.The sudden price rise can be attributed to growing investors’ optimism surrounding the company’s promising pipeline. Last month, the FDA granted orphan drug designation to Beam Therapeutics’ investigational genome-editing candidate, BEAM-101, ...

Rhythm Pharmaceuticals, Inc. (RYTM) shares rallied 36.6% in the last trading session to close at $89. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.3% loss over the past four weeks.The stock rallied after the company announced positive top-line data from a phase II study evaluating its investigational oral melanocortin-4 receptor (MC4R) agonist, bivamelagon, in patients with acquired hypothalamic obesity. ...

Vir Biotechnology, Inc. (VIR) shares soared 11.9% in the last trading session to close at $5.93. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.2% loss over the past four weeks.The sudden rise in the stock price can be attributed to the positive investor mindset regarding the potential of Vir Biotechnology’s only late-stage pipeline candidate, tobevibart. It is being developed in combination with Alnylam’s elebsiran, in a regi ...

Group 1: Stock Performance - CRISPR Therapeutics AG shares increased by 9.6% to close at $60.08, with notable trading volume compared to typical sessions [1] - The stock has gained 27.7% over the past four weeks, indicating strong investor interest [1] Group 2: Pipeline Developments - The rise in CRISPR's stock price is attributed to positive sentiment regarding its pipeline, particularly the in vivo candidate CTX310 targeting ANGPTL3 for atherosclerotic heart disease [2] - Updated data from an early-stage study showed a single dose of CTX310 resulted in peak reductions of up to 82% in triglyceride levels and up to 86% in LDL levels, generating excitement for other pipeline candidates [2] Group 3: Financial Expectations - The company is expected to report a quarterly loss of $1.54 per share, reflecting a year-over-year change of -3.4%, while revenues are projected at $5.89 million, a significant increase of 1032.9% from the previous year [3] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, suggesting that stock price movements may be influenced by trends in earnings estimate revisions [4] Group 4: Industry Context - CRISPR Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry, where Wave Life Sciences also operates, closing the last trading session 10.8% higher at $7.7 [4] - Wave Life Sciences has seen a consensus EPS estimate change of -6.6% over the past month, indicating a potential decline in performance compared to the previous year [5]

Adma Biologics (ADMA) ended the recent trading session at $18.34, demonstrating a +2.98% change from the preceding day's closing price. The stock outpaced the S&P 500's daily gain of 0.61%. On the other hand, the Dow registered a gain of 0.49%, and the technology-centric Nasdaq increased by 0.95%. Coming into today, shares of the infectious disease drug developer had lost 14.62% in the past month. In that same time, the Medical sector lost 0.67%, while the S&P 500 gained 3.85%. Market participants will be c ...

MiMedx (MDXG) shares soared 8% in the last trading session to close at $7. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.5% gain over the past four weeks.The sudden rise in price can be attributed to growing investors’ optimism related to the company’s efforts to develop and provide a leading portfolio of products for applications in the wound care, burn and surgical sectors of healthcare.This developer of biomaterials made f ...